BD Medical launches BD Neopak, a new prefillable syringe system for injectable drug delivery
BD Medical, a division of BD (Becton, Dickinson and Company), a leading international medical technology, has launched BD Neopak, a new system prefillable glass syringe specifically created for injectable drug delivery biopharmaceuticals. This new product is designed to address the challenges of the industry in the development, manufacturing and marketing of biologic drugs to patients.
The glass syringe BD prefillable Neopak provides biopharmaceutical companies and patients an even higher level of quality and device integration and improved container. Developed with a focus on quality and design, the product is manufactured in a fully indexed, which removes the glass to glass contact resulting in less visual defects and greater strength of the glass. The new process reduces levels of silicon while maintaining the functionality of suitable sliding force. Through tighter dimensional tolerances and limiting space dead volume glass syringe BD prefillable Neopak also reduces excess waste and refilling of biologic drug.
"In the current environment, regulators, patients and prescribers demand more quality and reliability in systems injectable drug delivery," said Claude Dartiguelongue, CEO of BD Medical - Pharmaceutical Systems. "The glass syringe BD prefillable Neopak is designed to reduce the risks associated with primary interactions between the container and the drug and drug products allows our customers get to market safely and effectively."
Seven of the 10 top-selling drugs in the world and more than half of the drugs currently in development are biologics. To support the development of drugs with syringe glass prefillable Neopak BD, BD offers customers a full range assessment services drug compatibility, functional requirements related to the drug and experience regulatory system for the recording medium for the product.
The glass syringe BD prefillable Neopak also offers more customization options for drug sensitive pharmaceutical partners through cross-silicone technology BD XSi (which reduces sub-visible particles while maintaining the functionality of the syringe) and technology ultralow tungsten. Moreover, advances in technology BD needle improve the patient experience and ensure reliable flow mechanisms more viscous drug formulations.
BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The company is dedicated to improving the health of people worldwide.